OUR STORY

nanopath was spun out of the Thayer School of Engineering at Dartmouth. 

We founded our company because we believe that the technology we've been developing in the lab can save lives.

​

At nanopath, we're passionate about improving the human condition through the development of life-saving technologies.  

OUR VISION

Our first product aims to dramatically shorten the diagnostic timeline for COVID-19 by eliminating nucleic acid amplification requirements. 

​

In addition to developing a state-of-the-art tool for centralized laboratories, we plan to develop a point-of-care system for use in low-resource settings and underserved communities.

​

​

​

OUR TECHNOLOGY

Our diagnostic harnesses advances in bioengineering and nanotechnology to sensitively and specifically detect viral, bacterial and fungal pathogens in complex biological matrices.

The technology platform has applications that extend beyond infectious disease, and include biosecurity surveillance, food and water safety, and cancer monitoring. 

Team

Dr. Amogha Tadimety

Co-Founder, CEO

Amogha is a leader in translational research. Her background combines deep scientific expertise in ultrasensitive biomarker detection with industry experience in life sciences consulting and venture capital. PhD, Thayer School of Engineering at Dartmouth

Alison Burklund

Co-Founder, CTO

Alison is pioneering novel approaches to rare biomarker capture and detection. She is a passionate about improving global health through the development of low-cost, rapid diagnostic systems.

 PhD Candidate, Thayer School of Engineering at Dartmouth ('21)

Dr. John Zhang

Co-Founder, Scientific Advisor

Dr. Zhang is an expert in biosensing and diagnostic microsystems. He is a Professor of Engineering and Director of the Laboratory for Micro and Nanotechnology in Bioengineering at Dartmouth College.

PhD, Electrical Engineering, Stanford University